A Study of Apatinib in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer

Summary

Apatinib is a tyrosin-inhibitor agent targeting at vascular endothelial growth factor receptor (VEGFR), and it's anti-angiogenesis effect has been viewed in preclinical tests. Phase I study has shown that the drug's toxicity is manageable and the maximum tolerable daily dose is 850 mg. The purpose of this study is to determine whether apatinib can improve progression free survival compared with placebo in patients with advanced non-squamous and non-small cell lung cancer who failed two lines of chemotherapy.

Timeline

Start

2010-03

Primary completion

2011-07

Completion

2011-09

Drugs

Indications